By Andrea Hargraves 
Candidate vaccine ‘also shown to be highly immunogenic, even in elderly participants’France Press agency
Posted on 05/08/2021 8:51 AM
Paris – The French-Austrian laboratory Valneva announced Thursday 5 “positive preliminary results” for the vaccine against chikungunya, which is currently undergoing phase three testing.
Valneva said in a statement that the vaccine tested on 4,115 adults in the United States produced “neutralizing antibodies in 98.5% of participants 28 days after a single injection.”
This number is well above the 70% limit for this immunization, agreed with the US regulatory body, the Food and Drug Administration, “for use in a marketing authorization application.”
The company said the candidate vaccine “also demonstrated to be highly immunogenic, even in older participants” and was “generally well tolerated”.
“These first results from a phase 3 (last before commercialization) trial of a chikungunya vaccine mean we are one step closer to addressing this important and growing unmet public health threat,” said Juan Carlos Jaramillo, medical director for the City of Valneva. , Quoted in the press release.
Final results are expected over the next six months, with the goal of bringing the product to market “as soon as possible”.
In addition to a vaccine against chikungunya, a virus transmitted by mosquitoes, Valneva is also developing an immune system against covid-19, which is currently in phase 3 clinical trials.
In addition, the Lyme disease serum is in phase II clinical trials in humans, which is the intermediate step to ensuring its efficacy.